PDGFRB and hepatocellular carcinoma: The efficacy of sorafenib against advanced HCC is attributed to its direct inhibitory effects on the growth of HCC cells via the Raf/MEK/ERK signaling pathway and its indirect suppressive effects on HCC angiogenesis via inhibition of receptor tyrosine kinases, including VEGFR and PDGFR (5, 23).